Licochalcone A suppresses Sp1 expression with potential anti‐myeloma activity

Código QR

Licochalcone A suppresses Sp1 expression with potential anti‐myeloma activity

Guardado en:

Detalles Bibliográficos
Autores principales:	Hua Bai, Min Zhou, He Zhou, Qiaoyan Han, Han Xu, Peipei Xu, Bing Chen
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b65f9510207a4561b9ed18f7a7bc74f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Xiaoyan Zhang, et al.
Publicado: (2021)

Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
por: Matthew A. Wall, et al.
Publicado: (2021)

Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
por: Laura Duran-Lozano, et al.
Publicado: (2021)

Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
por: Karina E. Zatolochina, et al.
Publicado: (2021)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Min Li, et al.
Publicado: (2021)

Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation
por: Tomoaki Mori, et al.
Publicado: (2021)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Mirian Brink, et al.
Publicado: (2021)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Alissa Visram, et al.
Publicado: (2021)

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT
por: Hee Jeong Cho, et al.
Publicado: (2021)

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
por: Carlos Fernández de Larrea, et al.
Publicado: (2021)

Anti-tumor effects of an ID antagonist with no observed acquired resistance
por: Paulina M. Wojnarowicz, et al.
Publicado: (2021)

Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C
por: Kuangguo Zhou, et al.
Publicado: (2021)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publicado: (2021)

Correction to: Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas
por: Faiqa Mudassar, et al.
Publicado: (2021)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Shebli Atrash, et al.
Publicado: (2021)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers
por: Yongxing Wu, et al.
Publicado: (2021)

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma
por: Katia Todoerti, et al.
Publicado: (2021)

lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC
por: Bohao Zheng, et al.
Publicado: (2021)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Huicheng Liu, et al.
Publicado: (2021)

Transcriptional suppression of CD8+ T cell exhaustion for improving T cell immunotherapy
por: Xue Yang, et al.
Publicado: (2021)

Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells
por: Federica Mannino, et al.
Publicado: (2021)

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Melissa K. Bennett, et al.
Publicado: (2022)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Chao Liu, et al.
Publicado: (2021)

Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment
por: Yuqi Wang, et al.
Publicado: (2021)

Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma
por: Rui Liu, et al.
Publicado: (2021)

Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma
por: Jesmin Akter, et al.
Publicado: (2021)

Identification of an Immune-Related Biomarker Model Based on the CircRNA-Associated Regulatory Network for Esophageal Carcinoma
por: Zhaonian Hu, et al.
Publicado: (2021)

Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
por: Ali Zahit Bolaman, et al.
Publicado: (2021)

Circulating microRNAs Correlate with Multiple Myeloma and Skeletal Osteolytic Lesions
por: Sara Reis Moura, et al.
Publicado: (2021)

Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1
por: Xiahui Li, et al.
Publicado: (2021)

Multiple myeloma
por: Larisa P. Mendeleeva, et al.
Publicado: (2021)

Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
por: Yuan Zhou, et al.
Publicado: (2021)

CCT8 recovers WTp53-suppressed cell cycle evolution and EMT to promote colorectal cancer progression
por: Qing Liao, et al.
Publicado: (2021)

MiR-186 Suppressed Growth, Migration, and Invasion of Lung Adenocarcinoma Cells via Targeting Dicer1
por: Juan Wang, et al.
Publicado: (2021)

Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer
por: Jingyi Wang, et al.
Publicado: (2021)

Retraction Note: A positive feedback loop consisting of C12orf59/NF-κB/CDH11 promotes gastric cancer invasion and metastasis
por: Zhang Jia-Xing, et al.
Publicado: (2021)

Correction to: ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma
por: Weipu Mao, et al.
Publicado: (2021)

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
por: Kwok-Kin Wong, et al.
Publicado: (2021)

MiR-101-3p Suppresses Progression of Cervical Squamous Cell Carcinoma by Targeting and Down-Regulating KPNA2
por: Hong Wang MM, et al.
Publicado: (2021)

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
por: Yuki Fujimoto, et al.
Publicado: (2021)